Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daptomycin intravenous - Merck & Co.

Next Previous
Drug Profile

Daptomycin intravenous - Merck & Co.

Alternative Names: Cubicin; Deptomycin; LY-146032; MK-3009

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer AstraZeneca; Banyu; Cubist Pharmaceuticals; Merck & Co; Novartis; Sunovion Pharmaceuticals Canada
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacteraemia; Bacterial endocarditis; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Phase III Osteomyelitis
  • Discontinued Community-acquired pneumonia; Urinary tract infections

Most Recent Events

  • 14 Sep 2022 Launched for Bacteraemia (In adolescents, In children, In infants) in Japan (IV) before September 2022
  • 14 Sep 2022 Launched for Methicillin-resistant Staphylococcus aureus infections (In adolescents, In children, In infants) in Japan (IV) before September 2022
  • 14 Sep 2022 Launched for Skin and soft tissue infections (In adolescents, In children, In infants, Complicated) in Japan (IV) before September 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top